Dr. Ruan on Lenalidomide Plus Rituximab in MCL

Jia Ruan, MD, PhD
Published: Monday, Jan 08, 2018



Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the combination of lenalidomide (Revlimid) plus rituximab (Rituxan) in mantle cell lymphoma (MCL).

The 5-year follow-up and correlative analysis from a phase II multi-center study of lenalidomide plus rituximab as initial treatment for patients with MCL was presented at the 2017 ASH Annual Meeting.

Ruan says that the aim of this study was to explore potential chemotherapy-free options for this patient population.
 
SELECTED
LANGUAGE


Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the combination of lenalidomide (Revlimid) plus rituximab (Rituxan) in mantle cell lymphoma (MCL).

The 5-year follow-up and correlative analysis from a phase II multi-center study of lenalidomide plus rituximab as initial treatment for patients with MCL was presented at the 2017 ASH Annual Meeting.

Ruan says that the aim of this study was to explore potential chemotherapy-free options for this patient population.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x